Thus, the hypertensive atrial substrate exemplifies how upstream mediators—such as Ang II, ROS, and TGF-β—can drive epigenomic dysregulation, and how their targeted modulation offers a rational and potentially transformative strategy in the prevention and treatment of AF. The gene discussed is TGFB1; the disease is atrial fibrillation.